Premium
The effects of (−)‐epigallocatechin‐3‐gallate (EGCG) and phosphatidylinositol 3‐kinase (PI(3)K) inhibition on Burkitt lymphoma cells
Author(s) -
Domina Aaron M.,
Van Doorn CarlChristian
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1167.3
Subject(s) - lymphoma , apoptosis , ly294002 , cancer research , cell culture , pi , burkitt's lymphoma , growth inhibition , cell growth , pi3k/akt/mtor pathway , phosphatidylinositol , epstein–barr virus , kinase , medicine , virus , microbiology and biotechnology , chemistry , biology , virology , immunology , biochemistry , genetics
Burkitt lymphoma, an aggressive non‐Hodgkins B cell lymphoma, is comprised of three major subtypes: sporadic, Epstein‐Barr virus‐associated, and HIV‐associated. A recent study has shown that an overactive phosphatidylinositol 3‐kinase (PI(3)K) pathway occurs in many Burkitt lymphomas and inhibition of this pathway leads to apoptosis (Schmizt R. et. al. , 2012). It has also been shown that the green tea compound, (−)‐epigallocatechin‐3‐gallate (EGCG) induces apoptosis in Burkitt lymphoma cells (Nakazato T. et. al. , 2005 and Noda C. et. al. , 2007). Therefore, the goal of this current study is to determine the relationship between EGCG treatment and the PI(3)K pathway. To this end, the effects of EGCG and the PI(3)K inhibitor, LY294002, on three sporadic Burkitt lymphoma cell lines, BL41–3, DG75, and Ramos were evaluated using an MTT assay and Western blot analysis. EGCG and LY294002 each inhibited Burkitt lymphoma cell growth in a dose‐dependent manner, although the degree of inhibition for each dose and the effect of combination treatment varied between the three cell lines, with the Ramos cell line showing the greatest decrease in viable cells. These results provide novel insight into the use of EGCG for the treatment of sporadic Burkitt lymphomas. This research was funded by the Husson University School of Pharmacy.